JP2022519327A5 - - Google Patents

Info

Publication number
JP2022519327A5
JP2022519327A5 JP2021546286A JP2021546286A JP2022519327A5 JP 2022519327 A5 JP2022519327 A5 JP 2022519327A5 JP 2021546286 A JP2021546286 A JP 2021546286A JP 2021546286 A JP2021546286 A JP 2021546286A JP 2022519327 A5 JP2022519327 A5 JP 2022519327A5
Authority
JP
Japan
Prior art keywords
fxa
patient
activity
inhibitor
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021546286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519327A (ja
JP7641903B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/017165 external-priority patent/WO2020163685A1/en
Publication of JP2022519327A publication Critical patent/JP2022519327A/ja
Publication of JP2022519327A5 publication Critical patent/JP2022519327A5/ja
Application granted granted Critical
Publication of JP7641903B2 publication Critical patent/JP7641903B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546286A 2019-02-07 2020-02-07 頭蓋内出血の治療方法及び効果の評価方法 Active JP7641903B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802645P 2019-02-07 2019-02-07
US62/802,645 2019-02-07
PCT/US2020/017165 WO2020163685A1 (en) 2019-02-07 2020-02-07 Methods for treating intracranial hemorrhage and assessing efficacy

Publications (3)

Publication Number Publication Date
JP2022519327A JP2022519327A (ja) 2022-03-22
JP2022519327A5 true JP2022519327A5 (https=) 2023-02-13
JP7641903B2 JP7641903B2 (ja) 2025-03-07

Family

ID=71947284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546286A Active JP7641903B2 (ja) 2019-02-07 2020-02-07 頭蓋内出血の治療方法及び効果の評価方法

Country Status (4)

Country Link
US (1) US20220125894A1 (https=)
EP (1) EP3920963A4 (https=)
JP (1) JP7641903B2 (https=)
WO (1) WO2020163685A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112071427B (zh) * 2020-09-07 2023-08-11 苏州大学 一种血液瘀滞预测方法及系统
WO2025080430A1 (en) * 2023-10-10 2025-04-17 Alexion Pharmaceuticals, Inc. Treatment of intracranial hemorrhage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064414A1 (en) * 2001-03-30 2003-04-03 Benecky Michael J. Rapid assessment of coagulation activity in whole blood
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
EP3121271B1 (en) 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
ES2605801T3 (es) * 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
ES2761730T3 (es) * 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3455636B1 (en) * 2016-05-13 2023-08-23 The Scripps Research Institute Compositions and methods for anti-thrombotic and hemostatic therapies
WO2018115235A1 (en) * 2016-12-22 2018-06-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antidotes to anti-coagulant drugs allowing diagnosis and treatment

Similar Documents

Publication Publication Date Title
Nilsson et al. Presence of contractile endothelin-A and dilatory endothelin-B receptors in human cerebral arteries
Roberts Tranexamic acid in trauma: how should we use it?
Yang et al. Dl-3-n-butylphthalide reduces neurovascular inflammation and ischemic brain injury in mice
Schneider et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor
JP6437458B2 (ja) 第Ｘａ因子の阻害を中和するための組成物および方法
JP4267592B2 (ja) 抗血栓薬薬効試験法
Herzog et al. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model
JP2022519327A5 (https=)
Devata et al. Use of GMI‐1271, an E‐selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis
JP2014529606A5 (https=)
JP2013528230A5 (https=)
Sakamoto et al. Safety of anticoagulant therapy including direct oral anticoagulants in patients with acute spontaneous intracerebral hemorrhage
Przykaza et al. Ligands of the neuropeptide Y Y2 receptors as a potential multitarget therapeutic approach for the protection of the neurovascular unit against acute ischemia/reperfusion: view from the perspective of the laboratory bench
Arruda-Junior et al. Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure
Choi et al. A multicenter, prospective, randomized clinical trial of marine mussel-inspired adhesive hemostatic materials, InnoSEAL Plus
KR20250024800A (ko) A형 및 b형 혈우병의 치료를 위한 피투시란
JP2017508806A (ja) 出血性疾患の治療における止血を改善するためのヒトプロトロンビン及び活性化第ｘ因子の組成物
JP6826040B2 (ja) 安全かつ効果的な血栓溶解（Ｔｈｒｏｍｂｏｌｙｓｉｓ）のための方法および組成物
Sharma et al. Efficacy and safety of the FXIa inhibitor milvexian for secondary stroke prevention: final results of the AXIOMATIC-SSP dose-finding randomized trial
JP7641903B2 (ja) 頭蓋内出血の治療方法及び効果の評価方法
Chatani et al. Preliminary insights into early ambulation and hemostasis after atrial fibrillation ablation using the Perclose vascular closure device
Sattler et al. Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia
Valenta et al. Protobothrops mangshanensis bite: first clinical report of envenoming and its treatment
Li et al. Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation
JP2007536230A (ja) ブタＢドメイン欠損ｆＶＩＩＩの投与方法